Pure Bioscience (PURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 07/31
(Values in U.S. thousands)
| 04-2026 | 01-2026 | 10-2025 | 07-2025 | 04-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,058 | 273 | 509 | 409 | 615 |
| Receivables | 242 | 252 | 389 | 474 | 287 |
| Inventories | 232 | 244 | 237 | 141 | 131 |
| TOTAL | $1,549 | $779 | $1,176 | $1,047 | $1,046 |
| Non-Current Assets | |||||
| PPE Net | 9 | 9 | 10 | 11 | 11 |
| TOTAL | $9 | $9 | $10 | $11 | $11 |
| Total Assets | $1,558 | $788 | $1,186 | $1,058 | $1,057 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 719 | 767 | 879 | 784 | 799 |
| Accrued Expenses | 181 | 149 | 176 | 154 | 173 |
| TOTAL | $3,654 | $3,055 | $3,159 | $938 | $972 |
| Non-Current Liabilities | |||||
| Long Term Debt | 3,743 | 4,006 | 3,573 | 5,236 | 4,899 |
| TOTAL | $3,743 | $4,006 | $3,573 | $5,236 | $4,899 |
| Total Liabilities | $7,397 | $7,061 | $6,732 | $6,174 | $5,871 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 130,018 | 111,887 | 111,887 | 111,887 | 111,887 |
| Common Shares | 1,301 | 1,119 | 1,119 | 1,119 | 1,119 |
| Retained earnings | -140,867 | -140,243 | -139,458 | -138,994 | -138,662 |
| TOTAL | $-5,839 | $-6,273 | $-5,546 | $-5,116 | $-4,814 |
| Total Liabilities And Equity | $1,558 | $788 | $1,186 | $1,058 | $1,057 |